55901-91-2

Basic information

• Product Name: 3(2H)-Pyridazinone, 6-(4-ethylphenyl)-4,5-dihydro-
• CAS NO: 55901-91-2
• Molecular Formula: C12H14N2O
• Molecular Weight: 202.256
• Mol File: 55901-91-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 3(2H)-Pyridazinone, 6-(4-ethylphenyl)-4,5-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 3(2H)-Pyridazinone, 6-(4-ethylphenyl)-4,5-dihydro-(55901-91-2)
• EPA Substance Registry System: 3(2H)-Pyridazinone, 6-(4-ethylphenyl)-4,5-dihydro-(55901-91-2)

Safety Data

• Hazardous Substances Data: 55901-91-2(Hazardous Substances Data)

Upstream product

• 49594-75-4 4-(4-ethylphenyl)-4-oxobutyric acid 
• 56705-44-3 methyl 4-(4-ethylphenyl)-4-oxobutanoate 
• 100-41-4 ethylbenzene 
• 17503-46-7 3--propionsaeure 

Downstream Products

• 1229037-20-0 6-(4-ethylphenyl)-2-(pyrrolidin-1-ylmethyl)-4,5-dihydropyridazin-3(2H)-one 
• 1229037-13-1 6-(4-ethylphenyl)-2-(morpholin-4-ylmethyl)-4,5-dihydropyridazin-3(2H)-one 
• 1229037-16-4 6-(4-ethylphenyl)-2-[(4-methylpiperazin-1-yl)methyl]-4,5-dihydropyridazin-3(2H)-one 
• 1229037-17-5 6-(4-ethylphenyl)-2-(1,2-dihydro-10H-phenothiazin-10-ylmethyl)-4,5-dihydropyridazin-3(2H)-one 
• 1427435-40-2 7-(4-ethylphenyl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine 
• 1427435-41-3 7-(4-ethylphenyl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-one 
• 1427435-42-4 7-(4-ethylphenyl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-thione 
• 1445852-89-0 C₁₃H₁₆N₂O₂ 
• 172542-40-4 3-(4-Ethyl-phenyl)-1,4,5,6-tetrahydro-pyridazine 

Relevant articles and documents

Synthesis, anti-convulsant activity and molecular docking study of novel thiazole pyridazinone hybrid analogues

Pyridazinone analogues have been known to be potential candidates for anticonvulsant agents. We have identified several pyridazinone-based anticonvulsant agents. As a continuation to our previous research, a series of hybrid pyridazinone-thiazole connected through amide linkage were designed and synthesized. Among these, compound SP-5F demonstrated significant anticonvulsant activity with median effective dose of 24.38 mg/kg (MES) and 88.23 mg/kg (scPTz). Results of GABA estimation showed a marked increase in the GABA level when compared with control. Molecular docking studies at the active site of GABA receptor, further confirmed the GABA modulatory effects of SP-5F.

Efficient synthesis, anticonvulsant and muscle relaxant activities of new 2-((5-amino-1,3,4-thiadiazol-2-yl)methyl)-6-phenyl-4,5-dihydropyridazin-3(2H) -one derivatives

A series of 2-(2-(3-(4-chlorophenyl)-6-oxo-5,6-dihydropyridazin-1(4H)yl) acetyl)hydrazine carbothioamide and 2-((5-amino-1,3,4-thiadiazol-2-yl)methyl)-6- (4-chlorophenyl)-4,5-dihydropyridazin-3(2H)-one derivatives were synthesized, characterized, and evaluated for anticonvulsant activity and muscle relaxant activity. The synthesized compounds 5d (82.75 %) and 5e (85.44 %) showed promising anticonvulsant activity by protection against tonic hind limb extensor phase in maximal electroshock model (MES) at (50 mg/kg) compared to standard drug phenytoin and also compounds 5d (82.75 %), and 5e (85.44 %) showed significant anticonvulsant activity by protection against pentylenetetrazole- induced generalized convulsions in pentylenetetrazole model (PTZ) at (100 mg/kg) compared to standard drug diazepam. On the other hand, compound 5e showed significant muscle relaxant activity (84.57 %) by rotarod and traction test model comparing with diazepam as a standard drug.

Design, synthesis and antihypertensive screening of novel pyridazine substituted s-triazin-2-imine/one/thione derivatives

Some new 7-substituted-phenyl-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3, 5]triazin-2-imine/one/thione derivatives were synthesized by a sequence of reactions starting from appropriate aryl hydrocarbons. The final compounds were screened for antihypertensive activities by non-invasive method using Tail Cuff method. All the test compounds showed significant antihypertensive activity; 7-(biphenyl-4-yl)-3,4,8,9-tetrahydro-2H-pyridazino[1,6-a][1,3,5]triazin-2-imine (4p) exhibited antihypertensive activity more than the reference standard drugs.